Chargement en cours...
Avelumab inducing hypothyroidism and hypoadrenalism: A case report and review of literature
Avelumab is an anti-PD-L1 (programmed death-ligand 1) immune checkpoint inhibitor (ICIs) and the monoclonal antibody that constitutes a major development in the immunotherapy of cancer. In 2017, The European Medicine Agency (EMA) approved it as an orphan drug for treatment of gastric cancer. Aveluma...
Enregistré dans:
| Publié dans: | EXCLI J |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Leibniz Research Centre for Working Environment and Human Factors
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6046621/ https://ncbi.nlm.nih.gov/pubmed/30034316 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.17179/excli2018-1357 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|